Recent preclinical and clinical studies showed an unexpected inverse relationship between obesity and the efficacy of PD‐(L)1 inhibitors, the so‐called ‘obesity paradox’ [34]. The gene discussed is CD274; the disease is obesity due to melanocortin 4 receptor deficiency.